Solutions from PCC to IND Drug Development

One-stop solutions with integrated project management and execution, and accelerating the clinical trail initiation for competitive advantages. Once a PCC antibody is determined, it takes about 12 months to complete the preclinical R&D and IND filing. Sanyou has completed the PCC-to-IND development of several client’s projects which have been submitted for IND in both China and the U.S.

Service Highlights

1. Integrated PCC-to-IND services

  • With our integrated services, only antibody sequence information is required for the IND approval.

2. Over 30 ongoing PCC-to-IND projects

  • The disease spectrum includes hematologic malignancy, solid tumors, autoimmune disorders, eye diseases, metabolic disorders, infectious diseases, etc.

3. Experience of 5 IND projects

  • 5 projects in the IND stage, with 1 application approved and 1 accepted.

4. IND delivery in 12 months

  • Integrated platforms enable 12-month delivery.

5. Various drug modalities

  • Various drug modalities such as monoclonal, bi-specific, trispecific antibodies and ADC.

6. Four sets of authorized host cells

  • Four sets of host cells supplied by Thermo Fisher, HORIZON, MERCK, and Quacells.

7. Antibody titer up to 12 g/L

  • Industry-leading antibody titer up to 12 g/L.

8. Antibody drug R&D team of 300 professionals

  • Team with extensive experience of project management and fast troubleshooting.

9. 100% successful deliveries

  • 100% successful deliveries guaranteed by advanced platform technologies and extensive R&D experiences.

10. Flexible and customized business model

  • Flexible cooperation options oriented for successful project development.

Popular articles

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more
Shanghai Model Organisms Jinshan R&D Base officially put into operation

After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.

Learn more